Ecteinascidin 770

• CAT Number: I013723
• CAS Number: 114899-80-8
• Molecular Formula: C₄₀H₄₂N₄O₁₀S
• Molecular Weight: 770.85
• Purity: ≥95%
• Target: Apoptosis
• Solubility: 10 mM in DMSO
• Storage: -20°C, protect from light
• IUPAC Name: [(1R,2R,3R,11S,12R,14R,26R)-12-cyano-5,6'-dihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2H-isoquinoline]-22-yl] acetate
• InChI: InChI=1S/C40H42N4O10S/c1-17-9-21-10-23-24(13-41)44-25-14-51-39(48)40(22-12-27(49-5)26(46)11-20(22)7-8-42-40)15-55-38(32(44)31(43(23)4)28(21)33(47)34(17)50-6)30-29(25)37-36(52-16-53-37)18(2)35(30)54-19(3)45/h9,11-12,23-25,31-32,38,42,46-47H,7-8,10,14-16H2,1-6H3/t23-,24-,25-,31+,32+,38+,40+/m0/s1
• InChIKey: BGFXHQYUWCGGLL-QWIBJBKUSA-N
• SMILES: CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)C#N)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O

Ecteinascidin 770 (Cat No.:I013723) is a 1,2,3,4-tetrahydroisoquinoline alkaloid known for its potent anticancer properties. It exhibits remarkable activity against U373MG cells, with an IC50 (half maximal inhibitory concentration) of 4.83 nM. ET-770’s anticancer mechanism is attributed to its ability to interfere with cancer cell proliferation and induce cell death. This compound holds promise as a potential therapeutic agent for the treatment of cancer, particularly in cases involving U373MG cells.

Reference

[1]. Tabunoki H, et al. Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids. Cancer Cell Int. 2012 Apr 11;12(1):14. [2]. Saktrakulkla P, et al. Chemistry of ecteinascidins. Part 3: preparation of 2//’-N-acyl derivatives of ecteinascidin 770 and evaluation of cytotoxicity. Bioorg Med Chem. 2011 Aug 1;19(15):4421-36.[3]. Powan P, et al. Ecteinascidin 770, a tetrahydroisoquinoline alkaloid, sensitizes human lung cancer cells to anoikis. Anticancer Res. 2013 Feb;33(2):505-12.